,48 The differences between the observed drug effects on traditional ‘LDL cholesterol’ and, both analytically and metabolically, more specific apolipoprotein B-containing lipoprotein subclasses are calling attention to the need for metabolic precision in the measurements of lipoprotein data and in assessing the role of lipoprotein metabolism in cardiovascular disease in relation to existing and novel lipid-altering therapies. Here, APOB is linked to cardiovascular disorder.